Methanol → 5-[2-(3,4,6,7,8,9-hexahydro-1H-pyrazino[1,2-a]indol-2-yl)-3-(hydroxymethyl)-4-pyridyl]-1-methyl-3-[[5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]-2-pyridyl]amino]pyridin-2-one

HRID 1021975Notes

Reaction equation

HRID 1021975 reaction equation
[CH2:1]1[C:6]2=[CH:7][C:8]3[CH2:9][CH2:10][CH2:11][CH2:12][C:13]=3[N:5]2[CH2:4][CH2:3][N:2]1[C:14]1[N:21]=[CH:20][CH:19]=[C:18]([C:22]2[CH:27]=[C:26]([NH:28][C:29]3[CH:34]=[CH:33][C:32]([N:35]4[CH2:40][CH2:39][N:38]([CH:41]5[CH2:44][O:43][CH2:42]5)[CH2:37][C@@H:36]4[CH3:45])=[CH:31][N:30]=3)[C:25](=[O:46])[N:24]([CH3:47])[CH:23]=2)[C:15]=1[CH:16]=[O:17].[BH4-].[Na+].CO>ClCCl>[CH2:1]1[C:6]2=[CH:7][C:8]3[CH2:9][CH2:10][CH2:11][CH2:12][C:13]=3[N:5]2[CH2:4][CH2:3][N:2]1[C:14]1[C:15]([CH2:16][OH:17])=[C:18]([C:22]2[CH:27]=[C:26]([NH:28][C:29]3[CH:34]=[CH:33][C:32]([N:35]4[CH2:40][CH2:39][N:38]([CH:41]5[CH2:42][O:43][CH2:44]5)[CH2:37][C@@H:36]4[CH3:45])=[CH:31][N:30]=3)[C:25](=[O:46])[N:24]([CH3:47])[CH:23]=2)[CH:19]=[CH:20][N:21]=1

Participants

5

Conditions

Temperature
0 °C

Procedure

A 50-mL single-neck round-bottomed flask was charged with 220b (100 mg, 1.0 eq., 0.15 mmol), NaBH4 (30 mg, 5.0 eq., 0.75 mmol), methanol (5 mL), and dichloromethane (5 mL). The mixture was stirred at 0° C. for 10 min and quenched with water (5 mL). It was then filtered and the filtrate was concentrated under reduced pressure. The residue was purified by reverse-phase prep-HPLC to afford the title compound (10 mg, 10%). MS-ESI: [M+H]+ 637.5. 1H NMR (500 MHz, DMSO-d6) δ 8.61 (d, J=2.0 Hz, 1H), 8.44 (s, 1H), 8.24 (d, J=5.0 Hz, 1H), 7.82 (d, J=3.0 Hz, 1H), 7.53 (d, J=2.0 Hz, 1H), 7.39-7.36 (m, 1H), 7.24 (d, J=9.0 Hz, 1H), 6.99 (d, J=5.0 Hz, 1H), 5.55 (s, 1H), 5.36-5.35 (m, 1H), 4.57-4.54 (m, 2H), 4.48-4.40 (m, 6H), 3.92-3.90 (m, 2H), 3.79-3.67 (m, 3H), 3.59 (s, 3H), 3.40-3.37 (m, 2H), 3.09-3.07 (m, 1H), 2.95-2.92 (m, 1H), 2.55-2.51 (m, 2H), 2.38-2.30 (m, 4H), 2.17-2.16 (m, 1H), 1.75-1.74 (m, 2H), 1.68-1.65 (m, 2H), 0.92 (d, J=6.5 Hz, 3H).

Workup

  1. customquenched with water (5 mL)
  2. filtrationIt was then filtered
  3. concentrationthe filtrate was concentrated under reduced pressure
  4. customThe residue was purified by reverse-phase prep-HPLC

Sources & evidence

ORD record
ord-38b5c55dca044711a4246f38bd624794
Source dataset
uspto-grants-2014_05
Patent number
US08716274B2

Reaction notes

Loading…